Clinical trials: Leukemia, Myeloid, Chronic-Phase
Leukemia, Acute, Myelodysplastic Syndromes
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell…
- Conditions
- Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia
- Trial name
- NCT05823571
- Testing
- Itacitinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
Phase I trial to study the effectiveness of PS-341 in treating patients who have refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia in blast phase, or myelodysplastic syndrome.
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00005064
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloid Leukemia
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
This study is a multicenter observational study aimed to investigate the efficacy and safety of olverembatinib dose reduction to 20 mg every other day (QOD) in patients with chronic myeloid leukemia (CML) in chronic phase or…
- Trial name
- NCT07383298
- Testing
- Olverembatinib 20mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qian Jiang
Chronic Myeloid Leukemia
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.
- Trial name
- NCT01490983
- Testing
- no access to eMedonline, eMedonline access
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Rex Cancer Center, Raleigh, NC
Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of vorinostat and azacitidine and to see how well they work in treating patients with myelodysplastic syndromes or acute myeloid leukemia.
- Conditions
- Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
- Trial name
- NCT00392353
- Testing
- Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 135 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloid Leukemia
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
- Trial name
- NCT07269470
- Testing
- Dasatinib, Ropeginterferon alfa-2b (P1101)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Lymphoblastic Leukemia, ALL
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Patients are being asked to participate in this study because treatment for their disease requires a stem cell transplant (SCT).
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML
- Trial name
- IL2 for GVHD (NCT00539695)
- Testing
- IL-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
This phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia.
- Trial name
- NCT02689440
- Testing
- Dasatinib, Laboratory Biomarker Analysis, Venetoclax
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML).
- Trial name
- NCT04155580
- Testing
- ASTX660, ASTX727
- Where
- 15 sites in United States
- Volunteers
- 68 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Leukemia, Myelodysplastic Syndromes
S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00996047
- Testing
- cytogenetic analysis, fluorescence in situ hybridization
- Where
- 280 sites in United States
- Volunteers
- 3,341 people
- Sponsor
- SWOG Cancer Research Network
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia
- Trial name
- NCT07719348
- Testing
- S241656, Posaconazole
- Volunteers
- 64 people
- Sponsor
- Servier
Chronic Myelogenous Leukemia
Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+
It is an open-label, randomized, double blind, placebo-controlled parallel-group, multi-center study to evaluate the efficacy and safety of Compound realgar formula Realgar-Indigo naturalis Tablet combined with Imatinib will be…
- Trial name
- NCT01755325
- Testing
- Compound realgar natural indigo Tablet
- Where
- 13 sites in China
- Volunteers
- 680 people
- Sponsor
- Junmin Li
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Myeloproliferative Neoplasm
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
There are 5 parts to this study for which the primary objectives are to evaluate safety, tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib…
- Trial name
- NCT04041050
- Testing
- Navitoclax, Ruxolitinib, Celecoxib
- Where
- 42 sites in United States, Belgium and 12 more
- Volunteers
- 85 people
- Sponsor
- AbbVie
Chronic Myeloid Leukemia
Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia
Fludarabine, cyclophosphamide, and rituximab (FCR) is the gold treatment for fit and young patients with Chronic Lymphoid Leukemia (CLL).
- Trial name
- VeRitAs (NCT03455517)
- Testing
- Venetoclax, Rituximab
- Where
- 31 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myelogenous Leukemia, Hematologic Malignancies
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory…
- Trial name
- NCT00660920
- Testing
- Ponatinib
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Ariad Pharmaceuticals
Chronic Myeloproliferative Disorders, Leukemia
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00293410
- Testing
- clofarabine, cyclophosphamide
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Lymphocytic, Acute, Leukemia
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched sibling donors.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Leukemia Acute Promyelocytic Leukemia (APL), Leukemia Acute Lymphoid Leukemia (ALL)
- Trial name
- NCT00185523
- Testing
- Allogeneic hematopoietic cell transplantation
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.